Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Laurens who wrote (1517)	3/18/1999 12:06:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

Laurens, thanks. I recall reading another study some months ago which showed that Alzheimer patients benefited from gingko biloba but gingko biloba doesn't help in prevention of Alzheimer. I'll see if I can dig out that article.

To: Laurens who wrote (1517)	3/19/1999 5:35:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

New Antidepressants as Effective as Older Ones, Easier to Use Bloomberg News Mar 19 1999 1:26PM ET New Antidepressants as Effective as Older Ones, Easier to Use Washington, March 19 (Bloomberg) -- Newer categories of antidepressants -- like Eli Lilly & Co.'s Prozac and Pfizer Inc.'s Zoloft -- are as effective as older drugs and are usually easier to take, say U.S. government researchers. The report, commission by the U.S. Department of Health and Human Services and complied by the San Antonio Evidence-Based Practice Center, examined the results of hundreds of clinical studies in one so-called meta-analysis. The study concluded newer drugs, the so-called selective serotonin reuptake inhibitors, weren't more effective than older tricyclic antidepressants. Still, patients are more likely to continue to take the newer drugs because they induce less severe side effects, researchers said. ''If you're looking to value to the patient, I think you have to take (side effects) into consideration,'' said Madhukar Trivedi of University of Texas Southwest Medical Center at Dallas, one of the researchers on the study. The report, Trivedi said, was designed to emphasize that doctors had a range of options in the treatment of depression. The report's suggestion that ''both newer and older antidepressants should be considered in making treatment decisions,'' doesn't mean the two classes of drugs are equal, said Ira Loss, an analyst who covers the pharmaceutical industry for HSC Washington Analysis. ''Anyone who thinks that the new antidepressants are no better than the old antidepressants has never dealt with someone who's been on antidepressants,'' he said. Patients who take newer antidepressants may suffer side effects like diarrhea and nausea, while the older class of the drug can produce weight gain, constipation or dizziness. Though both classes of drugs have side effects, those taking the newer drugs are far less likely to stop treatment because of those side effects, Trivedi said. The report also evaluated data on the effectiveness of three herbal remedies for depression: St. John's wort, kava kava and valeriana. According to the report, kava kava and valeriana weren't more effective than a placebo in treating depression. Citing studies in Germany, researchers said there was some evidence that St. John's wort may show promise in treating mild to moderate depression. Because the use and composition of St. John's wort varies from place to place, the limited number of trials using the remedy and the bias toward St. John's wort evident in those studies, researchers said it was difficult to conclusively evaluate the drug. A National Institute of Mental Health study is underway to further assess the safety and effectiveness of St. John's wort.